Display options
Share it on

Allergy Rhinol (Providence). 2017 Oct 01;8(3):126-131. doi: 10.2500/ar.2017.8.0207.

The study of a possible correlation between serum levels of interleukin 17 and clinical severity in patients with allergic rhinitis.

Allergy & rhinology (Providence, R.I.)

Mai Aly Gharib Aly, Mohamed Tawfik El Tabbakh, Waheed Fawzy Heissam, Said Hamed Abbadi, Shute

Affiliations

  1. From the Microbiology and Immunology Department, Faculty of Medicine, Suez Canal University, Ismailia, Egypt.
  2. ENT Department, Faculty of Medicine, Suez Canal University, Ismailia, Egypt.

PMID: 29070269 PMCID: PMC5662537 DOI: 10.2500/ar.2017.8.0207

Abstract

INTRODUCTION: Allergic rhinitis (AR) is one of the most common allergic diseases, which affects ∼20% of the world's population. T-helper (Th) type 2 cells produce interleukin (IL) 4 and IL-13, and mediate allergic responses, and these cytokines have been extensively studied as key players in the atopic airway diseases. However, the involvement of Th17 cells and IL-17 in AR has not been clearly examined.

AIM: To reevaluate AR clinical severity with serum IL-17, whether IL-17 affects the disease alone or in contribution with the atopic predisposition.

PATIENTS AND METHODS: During an 18-month period, 39 individuals were divided into three groups: A, (13 control), B (13 with mild-to-moderate AR), and C (13 with severe AR). Both group B and group C patients (26) were subjected to clinical examination and allergy skin testing, and to measurement of both total serum immunoglobulin E (IgE) and IL-17 levels. Eleven patients with AR then were exposed to 6 months of cluster immunotherapy, whereas the rest of the patients were not exposed.

RESULTS: Revealed a significant elevation of serum IL-17 levels with an associated increase in serum IgE in the patients with AR compared with controls and revealed that the serum levels of both total serum IgE and IL-17 decreased significantly after cluster immunotherapy.

CONCLUSION: These preliminary results added new data about the use of injective immunotherapy as well as reported on the use of sublingual immunotherapy.

References

  1. Am J Respir Crit Care Med. 2009 Oct 15;180(8):720-30 - PubMed
  2. J Allergy Clin Immunol. 2007 Apr;119(4):780-91 - PubMed
  3. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2010 Jan;24(2):53-6 - PubMed
  4. Zhongguo Dang Dai Er Ke Za Zhi. 2014 Dec;16(12):1206-10 - PubMed
  5. Lung. 2012 Oct;190(5):487-95 - PubMed
  6. Allergol Int. 2008 Jun;57(2):121-34 - PubMed
  7. Respir Res. 2006 Nov 03;7:135 - PubMed
  8. Asia Pac Allergy. 2013 Jul;3(3):186-93 - PubMed
  9. J Allergy Clin Immunol. 2012 Nov;130(5):1049-62 - PubMed
  10. Otolaryngol Head Neck Surg. 2003 Sep;129(3):274-9 - PubMed
  11. Allergy. 2003 Sep;58(9):905-11 - PubMed
  12. Curr Opin Otolaryngol Head Neck Surg. 2012 Feb;20(1):1-8 - PubMed
  13. Allergy. 2010 Feb;65(2):208-12 - PubMed
  14. Thorax. 2000 Oct;55 Suppl 2:S22-3 - PubMed
  15. Allergy. 2011 Aug;66(8):989-98 - PubMed
  16. Lin Chuang Er Bi Yan Hou Ke Za Zhi. 2006 Jul;20(14):625-7 - PubMed
  17. Allergy Asthma Proc. 2016 Jan-Feb;37(1):35-42 - PubMed
  18. Ann Allergy Asthma Immunol. 2008 Mar;100(3 Suppl 3):S1-148 - PubMed
  19. J Allergy Clin Immunol. 2017 Oct;140(4):950-958 - PubMed
  20. Immunol Lett. 2013 Nov-Dec;156(1-2):140-8 - PubMed
  21. Immunol Allergy Clin North Am. 2011 Aug;31(3):433-9 - PubMed
  22. Pediatr Allergy Immunol. 2010 Feb;21(1 Pt 2):e174-84 - PubMed
  23. J Allergy Clin Immunol. 2008 Aug;122(2 Suppl):S1-84 - PubMed
  24. Cytokine. 2015 Sep;75(1):181-5 - PubMed
  25. Ann Allergy Asthma Immunol. 2008 Dec;101(6):580-92 - PubMed
  26. Toxicol Pathol. 2012;40(2):205-15 - PubMed
  27. J Invest Dermatol. 2010 Nov;130(11):2621-8 - PubMed
  28. J Allergy Clin Immunol. 2011 Jan;127(1 Suppl):S1-55 - PubMed
  29. N Engl J Med. 2015 Jan 29;372(5):456-63 - PubMed

Publication Types